BCL2 and lymphoma: Given that apoptosis blockage is a key oncogenic mechanism in lymphoid malignancies, and that BCL-2 overexpression is a common finding in leukemias and lymphomas, many antagonists of anti-apoptotic BCL-2 have been developed and investigated for the treatment of hematological neoplasms [2, 6].